Table 2.
Subgroup analyses on study design.
| Study design (RCTs versus Cohorts) | Studies | Eyes | OR or MD (95%CI) | P | I2 |
| Postoperative UCVA of 20/20 or better | 8 | 1397 | OR 1.09 (0.62, 1.92) | .763 | 0.0% |
| RCT | 3 | 699 | OR 0.61 (0.08, 4.70) | .633 | 0.0% |
| Cohort | 5 | 698 | OR 1.15 (0.64, 2.06) | .647 | 0.0% |
| Postoperative UCVA | 7 | 1645 | MD 0.04 (0.01, 0.07) | .012 | 76.9% |
| RCT | 3 | 595 | MD 0.03 (−0.02, 0.08) | .180 | 56.2% |
| Cohort | 4 | 1050 | MD 0.04 (−0.00, 0.09) | .070 | 86.0% |
| Preoperative Q-value | 11 | 1605 | MD −0.00 (−0.02, 0.02) | .922 | 68.0% |
| RCT | 3 | 853 | MD −0.00 (−0.02, 0.01) | .668 | 0.0% |
| Cohort | 8 | 752 | MD 0.00 (−0.03, 0.03) | .935 | 75.0% |
| Postoperative Q-value | 11 | 1655 | MD −0.42 (−0.64, −0.21) | .000 | 98.4% |
| RCT | 3 | 853 | MD −0.48 (−0.77, −0.18) | .002 | 96.0% |
| Cohort | 8 | 802 | MD −0.41 (−0.68, −0.14) | .003 | 98.5% |
| Postoperative refractive SE | 6 | 1627 | MD 0.08 (−0.09, 0.25) | .336 | 95.4% |
| RCT | 3 | 1002 | MD 0.19 (−0.17, 0.54) | .299 | 98.0% |
| Cohort | 3 | 625 | MD −0.00 (−0.06, 0.05) | .897 | 0.0% |
| HOA | 10 | 1309 | MD −0.14 (−0.23, −0.06) | .001 | 98.5% |
| RCT | 4 | 827 | MD −0.10 (−0.17, −0.03) | .006 | 89.4% |
| Cohort | 6 | 482 | MD −0.16 (−0.26, −0.05) | .004 | 98.4% |
| Horizontal coma-like aberration | 5 | 404 | MD −0.00 (−0.03, 0.03) | .966 | 0.0% |
| RCT | 3 | 266 | MD 0.00 (−0.04, 0.05) | .816 | 0.0% |
| Cohort | 2 | 138 | MD −0.01 (−0.07, 0.05) | .688 | 0.0% |
| Vertical coma-like aberration | 6 | 455 | MD −0.01 (−0.03, 0.01) | .263 | 0.0% |
| RCT | 3 | 266 | MD −0.01 (−0.05, 0.03) | .577 | 0.0% |
| Cohort | 3 | 189 | MD −0.01 (−0.03, 0.01) | .331 | 0.0% |
| Spherical-like aberration | 12 | 1305 | MD −0.19 (−0.32, −0.06) | .004 | 99.2% |
| RCT | 4 | 599 | MD −0.24 (−0.69, 0.22) | .308 | 99.7% |
| Cohort | 8 | 706 | MD −0.16 (−0.25, −0.07) | .001 | 97.9% |